Fiscal
Year
2016
Annual
Report
MLSC FY16 Annual Reporti
Table of Contents
A Fully Integrated Life Sciences Ecosystem ii
The Bottom Line iii
Tax Incentive Fund & Business Development
Job Creation Tax Incentive Program 2
FY16 Business Development Updates 5
Capital Fund Update & Workforce Development
Investing in Infrastructure 7
STEM Equipment and Supplies Grant Program 8
Additional STEM Grants Update 9
Internship Challenge 11
Investment Fund Update, Next Steps, & The Way Forward
Funding the Companies of Tomorrow 14
Staying Connected 18
Next Steps 19
The Way Forward 21
Appendices
Capital Investment Awards (from Inception through June 30, 2016) 23
2015-2016 Internship Challenge Host Companies 25
Certified Active Life Sciences Companies (as of June 30, 2016) 28
MLSC Board of Directors (as of June 30, 2016) 30
MLSC Scientific Advisory Board (as of June 30, 2016) 31
MLSC Sta 32
MLSC FY16 Annual Report ii
As the new President & CEO of the Massachusetts Life Sciences Center, I have
joined the organization at an exciting time, for the MLSC, the industry and the
Commonwealth. As our agency has matured from a start-up operation to a
permanent and central part of our state’s economic development infrastructure,
Massachusetts has also matured into an integrated life sciences ecosystem, the
best place in the world for life sciences companies to develop new technologies
and therapies for patients, from discovery, right through to manufacturing and
commercialization. Companies from all over the world are coming to the same
conclusion: that Massachusetts is where they can nd the talent, investors, partners
in industry and academia, a supportive state government and other resources that
they need to be successful.
Massachusetts has achieved critical mass and then some – seventeen of the world’s
top twenty biopharma companies, and all ten of the world’s leading medical device
and diagnostics rms, now maintain a physical presence in Massachusetts. We
continue to actively recruit new arrivals, while encouraging and incentivizing our
home-grown companies to grow locally. And we continue to invest strategically,
in both the current needs of our industry, and in the assets that we will need in
the future. In this annual report you will nd a summary of our activities over this
past year to drive continued growth and to further strengthen our unparalleled life
sciences ecosystem.
We count ourselves at the Center as very fortunate to experience rsthand how
that ecosystem is driving the Massachusetts economy, contributing to improving
patient outcomes and reshaping the human experience through scientic discovery.
We meet with and learn from business and scientic leaders, local and civic
leaders, educators and academicians, employees and students from across the
Commonwealth with one goal in mind: supporting the growth and development of
our life sciences industry, the pre-eminent life sciences sector in the world.
Much has been accomplished, but there is much more work to do, and important
questions to answer. What can we do to address the unmet needs in Alzheimer’s
care, one of the leading causes of death in the United States for which there is no
available cure? What can we do to address the opioid epidemic ravaging not just
our state, but the nation, through non-opioid alternatives for pain management?
What programs and resources are needed to encourage the continued growth of
life sciences manufacturing in our state? And as policymakers begin the discussion
of “Life Sciences 2.0”, what resources and programs need to be put in place to
build on the progress we’ve made through the 2008 Massachusetts Life Sciences
Initiative?
We appreciate the ongoing strong support we are receiving in this work from
the Baker Administration, the State Legislature, and our partners in industry and
academia. I know that together, we can continue to make Massachusetts the
completely integrated ecosystem it needs to be for our life sciences sectors to
thrive, and for unmet patient needs to be addressed, both here in Massachusetts
and throughout the world.
A Fully Integrated Life Sciences Ecosystem
MLSC FY16 Annual Reportiii
The Bottom Line
As of June 30, 2016, the MLSC managed a portfolio of more than 600 grants and loans. Since its creation,
the agency has invested or committed more than $600 million, which has generated more than $2.3 billion in
additional investment in the Commonwealth. This has created a portfolio of more than $2.9 billion in public-
private investments in the state’s life sciences ecosystem.
The MLSC’s investment portfolio continued to grow in FY16 while, under new leadership, the agency has
been evaluating the effectiveness of past programs, and innovating new investment programs and initiatives
to address current opportunities in the marketplace.
FY16 investment commitment highlights include:
• Tax incentive awards totaling more than $20 million to 28 companies that committed to create more than
1,300 new jobs by the end of the 2016 calendar year.
• $3.7 million (an increase of $700,000 over the FY15 commitment) to support the placement of more than
400 interns at more than 200 companies across the state.
• $930,000 to support research and development collaborations between Massachusetts companies and
international research partners.
• $1.5 million awarded to support early-stage company development through the Accelerator Loan
Program.
• $100,000 for the development of the Life Sciences High School Apprenticeship Challenge promoting
hands-on STEM training for high school students.
$394,765,579
$113,920,545
$41,395,140
$27,256,555
$15,094,930
$13,472,246
$3,240,139
66 Capital Projects
122 Tax Incentive Awards
76 Company Grants & Loans
52 Academic Research Grants
More than 2600 Internships Funded
142 Equipment & Supply Grants for Schools and Organizations
62 Other Grants and Business Competitions
Tax Incentive Fund & Business
Development
MLSC FY16 Annual Report2
The Life Sciences Initiative authorizes up to $25 million in tax incentives each year for companies engaged in
life sciences research and development, commercialization, and manufacturing. Through this year’s program
the MLSC focused on achieving two goals: increasing the geographic diversity of life sciences investments
within Massachusetts, and targeting small and medium-sized life sciences companies. Toward that end, the
agency actively encouraged applications from companies of all sizes located outside of Greater Boston.
A total of 42 companies applied for tax incentives over the past year, and the MLSC awarded over $20
million to 28 awardees (see below). The companies receiving tax incentive awards committed to the creation
of 1395 new jobs in the Commonwealth. Companies receiving incentives must commit to the creation of a
specic number of net new jobs during a specied calendar year and also to the retention of those jobs for a
ve-year period.
Job Creation Tax Incentive Program
Company Location Incentive Amount Jobs
908 Devices Inc. Boston $165,000 11
AbbVie Inc. Worcester $525,000 35
Abiomed, Inc. Danvers $1,050,000 70
Alnylam Pharmaceuticals, Inc. Cambridge $2,250,000 150
Amgen Inc. Cambridge $780,000 52
Baxalta US, Inc. Cambridge $1,320,000 66
Charles River Laboratories, Inc. Wilmington $1,200,000 80
Emulate, Inc. Boston $318,090 30
Enanta Pharmaceuticals, Inc. Watertown $360,000 24
Ginkgo Bioworks, Inc. Boston $483,377 50
Juno Therapeutics, Inc. Waltham $165,000 11
LFB USA, Inc. Framingham $720,000 48
Masy Systems, Inc. Pepperell $150,000 10
Merrimack Pharmaceuticals, Inc. Cambridge $225,000 15
Moderna Therapeutics, Inc. Cambridge $1,875,000 125
Nitto Denko Avecia Inc. Milford $450,000 30
Nova Biomedical Corporation Waltham $750,000 50
Pharmalucence, Inc. Billerica $150,000 10
Quanterix Corporation Lexington $225,000 15
Radius Health, Inc. Waltham $525,000 35
Sarepta Therapeutics, Inc. Cambridge $750,000 50
Seres Therapeutics, Inc. Cambridge $945,000 63
Shire Human Genetic Therapies, Inc. Lexington $3,235,000 220*
Siemens Healthcare Diagnostics, Inc. Walpole $735,000 30
SQZ Biotechnologies Company Boston $129,784 20
STC Biologics, Inc. Cambridge $150,000 10
Takeda Pharmaceuticals America, Inc. Cambridge $1,125,000 75
Web Industries Boston, Inc. Holliston $150,000 10
FY16 Tax Incentive Awardees
*Shire was awarded $985,000 in early FY16 as a result of its commitment to add 70 new jobs in the 2015
calendar year
MLSC FY16 Annual Report 3
• Some awardees have declined their awards due to changes in their business or general economic conditions.
• Some awardees have also determined that they were unlikely to reach their job creation commitment under
the statutory guidelines and opted to voluntarily terminate their agreements, either by foregoing taking the tax
benets at all or by returning the benets to the Commonwealth if they had already received them.
• Since inception, the MLSC has decertied two awardees for not achieving the statutory thresholds. A total of 26
active companies have received two or more active awards, illustrating their continued commitment to growing
their headcount in the Commonwealth.
• As of December 31, 2015, awardees from the 2009 through 2014 programs had hired and maintained 7,779
employees, representing a 173% percent attainment of their commitments.
• As of June 30, 2016, there were 100 active awards from the 2011 through 2015 program years, with a combined
4,466 commitment of fullling or maintaining new hires under the program.
• The awardees from the 2009 and 2010 programs completed their 5 year term on December 31, 2014 and
December 31, 2015 respectively and no future reporting is required.
• The awardees from the 2011 program will complete their 5 year term on December 31, 2016. The results of these
awards will be reported to the MLSC in January 2017.
• As of June 30, 2016, the Tax Incentive Program has resulted in combined net new hire commitments or actual new
hires of 5,408 jobs among active and completed awards.
Summary of the Tax Incentive Program from Inception to June 30, 2016
Program Year Number of Awards
Provided
Dollar Amount of Awards
Provided
Number of Active Awards
as of June 30, 2016
Dollar Amount of Active
Awards as of June 30, 2016
2011 26 $20,340,884 18 $12,208,937
2012 24 $22,992,583 20 $18,920,583
2013 32 $24,498,182 25 $15,219,328
2014 12 $20,000,000* 10 $17,660,000
2015 28 $19,921,251 27 $19,696,251
Total Active 122 $107,752,900 100 $83,705,099
Program Year Number of Awards
Provided
Dollar Amount of Awards
Provided
Number of Completed
Awards as of June 30, 2016
Dollar Amount of
completed Awards as of
June 30, 2016
2009 Completed 26 $24,420,000 10 $13,049,260
2010 Completed 24 $24,390,292* 12 $17,166,186
Total Completed 50 $48,810,292 22 $30,215,446
Total 172 $156,563,192 122 $113,920,545
The MLSC carefully monitors the performance of companies that have received tax incentives to ensure
compliance with the headcount commitments they are required to reach per their agreement with the
Center. As part of the MLSC’s agreements with awardees, recipients of tax incentives are required to
report job creation results to the Center by the end of the calendar year. Under the Life Sciences Act, the
Department of Revenue has the authority to recover or “claw back” incentives from companies that the
MLSC determines will not meet the minimum job creation threshold in their tax incentive agreement.
*Shire HGT, Inc., of Lexington received additional tax incentives of $3.5 million for the 2010 program and $985,000 for the 2014 program under
an existing tax commitment by the Commonwealth.
Emulate, Inc. opened its new headquarters and laboratories in Boston’s Seaport District in February,
2016. The new facility is a workplace for the company’s 40 employees, with plans for expansion to
85 employees within the coming year. The 20,000 square-foot expanded headquarters provides
state-of-the-art laboratories and facilities to support commercial activities, product development,
and collaborative research programs for the company’s Organs-on-Chips technology.
Based on the commitment to create 30 net new jobs in Massachusetts this calendar year, the
Center approved Emulate’s rst tax incentives totaling $318,090 to support the company's growth.
MLSC FY16 Annual Report 5
FY16 BUSINESS DEVELOPMENT UPDATES
FY16 saw the continued arrival of numerous domestic and international companies to the Massachusetts
life sciences community. Many existing companies also announced expansions of their current operations in
Massachusetts. Below is a rundown of some of these companies and their announcements.
• In June 2016, Pzer broke ground on a new clinical manufacturing facility in Andover. Pzer will invest
more than $200 million in the development of the 175,000 sq. ft. state-of-the-art facility. When complete,
the facility will provide 75 new permanent manufacturing jobs.
• Siemens Healthcare Diagnostics announced plans for expansion of its manufacturing plant in Walpole.
The $300 million dollar expansion will provide a minimum of 400 jobs in a facility of over 700,000 sq. ft.
• Eurons Lancaster Labs (Worldwide) opened its Northeast ofce in the Cambridge Innovation Center.
• Zumutor (India) announced plans to establish the company’s rst full-time U.S. operations in the Boston
area. The new ofces, located at 100 Trade Center in Woburn and 303 Wyman Street, Waltham, will
house the company’s global headquarters and business development activities.
• Biose (France) opened its rst US ofce in the Cambridge Innovation Center.
• Brammer Bio announced plans to build-out a 50,000 sq. ft. facility in Lexington dedicated to late phase
development of viral vector-based and cell-based advanced therapies. The facility will house 50 new jobs
and be qualied and operational by Q2 of 2017.
• Anagenesis Biotherapies (France) opened its rst U.S. ofce at the Cambridge Innovation Center.
• CeQur expanded its Marlborough location to 25,000 sq. ft., and plans to increase its workforce from 50
employees to 150 over the next 24 months.
• Affera, Inc. announced its move to a larger facility and is actively hiring to ll its new 5,395 sq. ft. facility in
Watertown.
• Biognosys (Switzerland) announced plans to open its rst North American location in the Greater Boston
area.
• In March 2016, Bayer (Worldwide) announced its plans to open a new life sciences center in Cambridge.
This East Coast Innovation Center will help the German drugmaker further develop its R&D presence in
the area and build on existing relationships with the Broad Institute of MIT and Harvard.
• Bristol-Myers Squibb celebrated the expansion of its Devens manufacturing facility. The expansion
added 200,000 sq. ft., with 350 new jobs coming to that location.
• GE Healthcare held the opening for its new North American headquarters in Marlborough, which will
house 200 new jobs in 210,000 sq. ft. of space.
• Simcere Pharma (China) expanded to Cambridge, its second location in North America.
• Valirix Plc (United Kingdom) opened its rst North American ofce in Kendall Square.
• Vantix Diagnostics announced the relocation of its US headquarters from New Hampshire to the
University of Massachusetts Lowell Innovation Hub.
• Jana Care (India) announced the establishment of its rst US ofce based out of the Business Innovation
Center at Boston University.
• Cyclica (Canada) announced the establishment of its US ofce at the Cambridge Innovation Center.
• Selvita (Poland) established its North American headquarters in Cambridge.
• Applied Photophysics (United Kingdom) located its North American operations at the Cummings Center
in Beverly.
• Fiore Healthcare Advisors (New Jersey) opened a local ofce in Cambridge.
• Unum Therapeutics announced the move of its company headquarters into new, 33,000 sq. ft. ofce
and laboratory facilities in Cambridge. This expansion came just one year after the company’s launch at
LabCentral in Kendall Square.
Capital Fund Update & Workforce
Development
MLSC FY16 Annual Report 7
Investing in Infrastructure
The MLSC’s investments in infrastructure are funded through its Capital Fund. Half of the resources
committed to the Life Sciences Initiative ($500 million) are dedicated to capital infrastructure projects.
The MLSC uses its Capital Fund to strategically invest in four key areas:
• Infrastructure investments to accelerate innovation
• Programs designed to train the next generation of life sciences talent
• Working spaces for early stage companies
• Municipal infrastructure to support life sciences growth
Investments in these areas have been awarded on a competitive basis to research hospitals, non-prot
organizations, universities, and small business incubators in every region of the Commonwealth.
To date, MLSC infrastructure investments have contributed or will contribute to the creation of more than 1.6
million square feet of new life sciences research and manufacturing space across the Commonwealth, while
creating more than 4,800 jobs in the building trades and in the life sciences.
In FY16, the MLSC saw the completion of funding for 11 projects representing more than $22.9 million in
investments. The total number of projects where MLSC funding is complete is now 34, representing $213
million in investments. A new round of the Competitive Capital Program was launched in May 2016, and
applications are currently under review.
Regis College Contributes to Job Readiness
FY16 saw the culmination of a $355,000 Capital Fund investment as Regis College opened its newly
renovated science laboratory. The college, which serves a diverse population of students, many the rst
in their families to attend college, invested in state-of-the-art scientic equipment to support biology and
biochemistry studies, including a Vertical Laminar Flow Hood, a minus-86 degree freezer, an inverted phase
contrast microscope, a glass still for puried water, centrifuges, and a Countess II cell counter – all of which
will advance student tissue culture training and research. Regis was awarded the funds in 2015 to strengthen
the science learning opportunities on campus and foster regional partnerships.
“We are focused on accelerating STEM learning to help more students fully
participate in today’s innovation economy. We are very appreciative to Travis
McCready and the Massachusetts Life Sciences Center for their tremendous
support.”
- Antoinette M. Hays, PhD, RN., President of Regis College
MLSC FY16 Annual Report8
STEM Equipment & Supplies Grant Program
The STEM (Science, Technology, Engineering and Math) Equipment and Supplies Grant Program enables
the purchase of equipment and supplies for high schools and middle schools in the Commonwealth in order
to train students for life sciences careers. Consistent with the goals of the Massachusetts STEM Plan, the
program seeks to increase student achievement and student interest in STEM elds, as well as supporting
the implementation of the state's STEM standards.
Vocational technical high schools, public high schools and middle schools located in Gateway Cities,
and public high schools and middle schools with a student population of at least 25% designated by the
Massachusetts Department of Elementary and Secondary Education as “economically disadvantaged,” are
eligible to apply for up to $100,000 in grant funding. Applicants seeking funding of greater than $100,000
(but no more than $250,000) are required to secure matching funds, in cash or as an in-kind donation, for any
amount over $100,000 from an industry partner. To date, the program has awarded over $13 million to more
than 100 different schools throughout Massachusetts and leveraged more than $1 million in matching funds
from industry partners.
By focusing on underserved and low-income communities, the MLSC is working to increase the diversity of
students who are trained and prepared to positively impact the state’s future life sciences workforce.
In FY16, 44 grant recipients representing 77 schools received funding for equipment and supplies purchases
totaling more than $3.7 million. In May 2016, the MLSC announced a new solicitation for FY17 funding.
Next year’s program will offer funding for teacher professional development to ensure that all recipient
schools have teachers that are trained to use the equipment and have access to relevant curricula to support
learning goals throughout the academic year.
Lowell High School Life Sciences Maker Space
The Lowell High School (LHS) Life Sciences Maker Space, funded through a $100,000 grant from the Center
that was awarded in FY15, opened in May 2016, and is outtted with high powered microscopes, life
sciences lab supplies, computers with technical computing software, 3-D printers, and more.
Starting next year, each Lowell High School Freshman will spend at least one week of their biology period
per year at the Maker Space, making their life sciences learning hands-on and authentic. Unlike other Maker
Spaces throughout the country, LHS Life Sciences Maker Space is a rare one that focuses specically on
life sciences. The Maker Space, operated in part by UMass Lowell, complements the M2D2 Life Science
Entrepreneurship high-school course where students pitch medical-device ideas for the university's
DifferenceMaker Idea Challenge.
The LHS Maker Space has offered each student a change of pace from the regular classroom. It has
provided students a space for inspiration, design and collaborative thinking. Through the LHS Maker Space,
students and teachers have had the chance to explore new technology together and developed many
project ideas for the future.
MLSC FY16 Annual Report 9
High School Apprenticeship Program
In FY16, the Life Sciences High School Apprenticeship Challenge training program was launched and
funded through a $100,000 investment from the Massachusetts Life Sciences Center. The goal of the
program is to train local, underserved high school students interested in life science and biotech careers, so
they can be solid contributors at the laboratory bench. The training, led by BioBuilder and hosted by MIT,
taught 27 students from diverse backgrounds laboratory and professional skills that will prepare them for
internship opportunities and eventual careers with local life sciences companies and research institutions.
The eight-week training program received generous support from Cold Spring Harbor Laboratory Press,
which donated $3,000 worth of lab books, and MIT’s Department of Biological Engineering, which provided
lab and classroom space for the students.
The program graduated the rst class of students on May 19, 2016. A number of the graduates were then
placed in paid summer internships at institutions such as Massachusetts General Hospital and Cambridge-
based life sciences companies such as AB Biosciences and Abcam. Intern stipends of up to $2,880 (based on
$12/per hour for six weeks) will be reimbursed by the MLSC.
With the launch of this program, the MLSC now supports a pipeline of workforce training that spans from
middle school through graduate school.
“I learned a lot of biology that I didn’t learn in high school, and developed
better laboratory skills. I think the most important thing I learned is how to
communicate with people that I have never met before to make a scientic
poster with them.”
Jefferson Lopez-Garcia of Boston, a graduate of the program
Additional STEM Grants Update
In FY16 Talbot Middle School in Fall River, last year’s winner of the MLSC Space Station STEM Challenge, got a
visit from the team at the Center for the Advancement of Science in Space (CASIS) and astronaut Fred Gregory.
The visit helped progress the students’ International Space Station (ISS) bound project on the development of
tadpoles in UV-B light found in space. Students further prepped their NanoLab, which will house the experiment
on the way to, and on, the ISS. Afterwards, students listened to Mr. Gregory describe what space-based research
can offer us now and in the future.
MLSC FY16 Annual Report 11
Training the Next Generation
The Internship Challenge has continued to be the MLSC’s agship workforce development program.
The year-round program is designed to expand the pool of prospective employees who have practical
experience, enhance opportunities for mentoring, enable more students to explore career opportunities,
and expose students to entrepreneurship. To date, the program has created more than 2,600 paid internship
opportunities at over 560 life sciences companies throughout the Commonwealth. Interns have represented
nearly 190 different colleges and universities.
The Internship Challenge focuses on enhancing the talent pipeline for life sciences companies while
providing students and recent graduates with practical, “hands-on” experience that prepares them to step
into the workforce ready to meet the job requirements of life sciences employers. The program subsidizes
paid internships for undergraduate sophomores, juniors and seniors, community college students, Masters
students; and recent college graduates.
In FY16 the MLSC updated its online interface used to connect host companies with student candidates.
This update provides an easier and more accessible process for students to complete an online application
and for host companies to review applications to match students' skills with their needs.
As in past years, host companies could hire up to two interns per year, but had the option to hire an
additional two interns that are enrolled in a community college. At the conclusion of the internship, the
MLSC reimburses companies for intern stipends of up to $8,160, up from $7,200 in past years, due to a
$700,000 increase in funding. This allows for 12 weeks of full-time work at the maximum reimbursable pay
rate of $17 per hour, increased from $15 per hour that was offered in previous years.
Internship Challenge Participants by Major
Engineering
Biology
Business
Chemistry
Computer Science
Pharmaceutical
Sciences
Neuroscience
Health Sciences
Regulatory Affairs
Pre-Medical
Physics
Information Technology
Psychology
Mathematics
Laboratory Tech.
Training
Other (Misc.)
5%
35%
29
%
10
%
7
%
4
%
2
%
2
%
1
%
Each
MLSC FY16 Annual Report12
Internship Challenge Impact Across Massachusetts
The Internship Challenge serves as a human-capital subsidy program for small and early-stage companies.
Because participating interns work in smaller companies, they also receive exposure to a dynamic
entrepreneurial environment. Students from more than 280 (nearly 80%) of the 351 cities and towns in
Massachusetts have benetted from the Internship Challenge Program, while companies from over 120 cities
and towns have brought on interns through this program.
“I learned more than I have in any semester at Brown.”
J
ackie Alois, of Andover, Massachusetts, will be a senior at Brown University this fall. This past summer
she was awarded an internship at Bach Pharma in North Andover.
“My critical thinking skills were exponentially sharpened. I had to research and understand all that Bach
Pharma's drug has proved in various animal models and create evidence for how the drug can slow the
progression of this devastating disease. I learned how to intertwine these pieces of information to tell a story
and convey a powerful message. “
“In this time I have gotten a crash course on the biology of ALS, as well as the steps needed to advance
Bach Pharma's lead candidate into patients who have ALS. I learned more than I have in any semester at
Brown. I attribute all of the knowledge that I have gained to the Internship Challenge. I am not sure where
I will end up in the next year after college, but Bach Pharma has given me the tools necessary to succeed in
any endeavor that I may take on.”
"Working for a start-up right out of college was an absolute game-changer for
me; not only did I have a great deal of responsibility in a newly established lab,
but was also able to play a role in the early stages of the company. I am now
an Associate R&D Engineer at Access Vascular, and am grateful for the strong
foundation that my internship gave me for a career with Access Vascular and
for future endeavors in the life sciences eld."
- Felicity Meyer, Associate R&D Engineer, Access Vascular
Investment Fund Update, Next
Steps, & The Way Forward
MLSC FY16 Annual Report14
In FY16, the MLSC continued its commitment to entrepreneurship and the pipeline of new life sciences
companies in Massachusetts by selecting two early-stage companies for Accelerator Loans totaling $1.5
million. From the Accelerator Loan Program’s inception through the end of FY16, the MLSC has funded
or committed to lend a total of $23.1 million in Accelerator Loans to 33 early-stage companies. To date,
Accelerator companies have raised more than $250 million in funding and acquisition proceeds subsequent
to receiving a loan from the MLSC.
During FY16, the MLSC administered the twelfth round of the Accelerator Loan Program, receiving a total
of 21 applications, 18 of which were eligible for review by experts selected from among the MLSC’s 200-
plus volunteer peer reviewers. The MLSC’s peer reviewers recommended 13 of these applicants for review
by the MLSC’s Scientic Advisory Board (SAB). Three companies were then recommended by the SAB for
due diligence and review by the Investment Subcommittee of the MLSC’s Board of Directors. Two of these
companies were approved for a loan by the full Board of Directors.
Accelerator loans have provided working capital to early-stage life sciences companies at a critical stage
in their development. This program seeks to de-risk companies for future – usually private – investment
by funding the steps necessary to achieve critical milestones. Some of these companies may hold the
promise of developing cures for the rarest diseases, while others will be acquired by large companies that
are increasingly dependent on external innovation for growth. Massachusetts’ robust culture of new idea
generation remains a key driver in attracting early-stage companies to set up operations here. Leading
companies in life sciences are also drawn to expand in Massachusetts to gain access to key advances that
are taking place here.
Funding the Companies of Tomorrow
Accelerator Loans awarded in FY 2016
First Light Biosciences, Inc. in Bedford was awarded $750,000. First Light develops rapid tests to
detect all types of hospital infections and identies infectious agents causing them to determine the
best antibiotic treatment.
MX Orthopedics, Corp.* in Lexington was also awarded $750,000. Their work involves developing
effective orthopedic devices made from the shape memory alloy Nitinol.
*MX Orthopedics declined their Accelerator Loan Award after being acquired in August of 2016.
In 2011, Allurion received $750,000 in funding through the MLSC’s Accelerator
Loan Program, and the company has since raised over $14 million in follow
on funding. At the time of its award, Allurion had 3 employees. The company
has now grown to 16 employees, and is planning a 20 percent increase in its
workforce by the end of 2016. Allurion has also served as a host company
for the MLSC’s Internship Challenge Program, hosting seven interns to date
for which they have or will receive salary reimbursement through the MLSC.
The Elipse gastric balloon for weight loss received a CE mark late last year,
the company’s rst regulatory approval allowing sale of the product in the
European Union. Elipse is currently available in select weight loss centers in
France, Italy and the U.K., with plans for a US clinical trial in 2017.
MLSC FY16 Annual Report16
During FY16 the MLSC tracked the progress of other early stage companies that received funding through
our Milestone Achievement Grant Program and our Universal Partnerships (UP) Grant Program, and
provided six additional grants through the UP Program.
Milestone Achievement Program
In FY15, the MLSC launched a grant program, known as the Milestone Achievement Program (MAP). This
program was intended to support early-stage life sciences companies in need of completing a critical
milestone in order to attract additional outside funding and propel the future development of their
technology. The MLSC Board of Directors approved awards to twelve companies for a total of over $2
million in grants, enabling these companies to continue work on fundamental milestone projects.
Of particular mention, in 2015, Akita Innovations, Inc. was accepted as a member of the National
Armaments Consortium (NAC), a group of more than 340 companies and universities working together with
the Department of Defense to enhance our Warghter’s lethality, survivability, and combat effectiveness.
Akita Innovations was also awarded a Phase I SBIR contract by the Defense Threat Reduction Agency to
develop and scale a method of production for a stabilized biocidal oxidizer material.
Aquinnah Pharmaceuticals announced in 2015 that it received a $5 million investment from Takeda
Pharmaceutical Company, Ltd, in its rst private equity nancing. The company is developing drugs to ll the
gap in the elds of ALS, protein and RNA regulation, and other neurodegenerative diseases.
Lastly, in 2016, Micro-Leads announced that it is contributing medical electronics system design in the
Defense Advanced Research Projects Agency (DARPA) Hand Proprioception and Touch Interfaces (HAPTIX)
program to create a prosthetic hand system that moves and provides sensation like a natural hand.
Universal Partnerships Program
The Universal Partnerships Program (UP) was launched in FY14 and reects the MLSC’s commitment to
further strengthen Massachusetts’s global leadership position in the life sciences, to drive future economic
growth and employ new models of collaboration. The UP program provided grants to Massachusetts
companies to support an R&D collaboration with a non-U.S. organization (such as: a company, research
institution, or university). In FY 2016, the MLSC Board of Directors awarded six Massachusetts companies
with $930,000 in grant funding.
Milestone Achievement & Universal Partnerships Program Updates
Company Location Partner Partner Location Amount Awarded
Akili Interactive Labs Boston Starlab Barcelona, Spain $190,000
DetectoGen Westborough
Universidade Federal de Minas
Gerals
Brazil $200,000
LX Medical Westwood
BC Cancer Agency Research
Center
Vancouver, BC,
Canada
$70,000
Agile Devices Cambridge Agile MV
Montreal, QB,
Canada
$100,000
Akrivis Technologies Salem/Cambridge CEA-Leti Genoble, France $174,705
Revolution
Biosciences
Boston Merck Serono Darmstadt, Germany $195,000
Previous awardees through the program continued to make progress this year. Felicitex Therapeutics
earned an UP grant to pursue a project related to new targets for cancer. Working with their partner, Selvita
the largest drug discovery company in Central and Eastern Europe, they have made progress towards
identifying a new target. Additionally, Selvita decided to expand closer to its partners and clients and open
a fully-owned US subsidiary in Cambridge, Selvita Inc.
In 2015, Cambridge-based Platelet Biogenesis, who develops sterile, longer lasting
human platelets for on-demand availability, was awarded a $200,000 grant through the
MLSC’s Life Sciences Milestone Achievement Program (MAP).
"Being awarded the MAP Grant from the Center enabled us to hire our rst full time
employee, move to our current space and purchase much needed equipment. We've
since grown to 3 full time employees, with plans to double that number by year's end,
and we plan to utilize the MLSC Internship Challenge Program and hire our rst intern
for the upcoming fall semester. In addition to successfully raising a private nancing
round, we were recently awarded a 'Golden Ticket' to LabCentral, and a $1.5M SBIR
grant from the NIH/NHLBI, which have helped to substantially accelerate our work."
- Jonathan Thon, Ph.D., Co-Founder of Platelet Biogenesis
Platelet BioGenesis
MLSC FY16 Annual Report18
Staying Connected
The MLSC’s communications and marketing program keeps stakeholders and the general public informed
about the MLSC’s investment of public dollars, promotes public accountability for the MLSC’s progress in
accomplishing its mission, and provides ongoing updates and information exchange with the life sciences
community in order to encourage its involvement and input.
In FY16, communication and marketing efforts remained a key part of attracting a robust and diverse pool
of applicants for MLSC programs, in addition to engaging with prospective companies for expansion and
relocation in Massachusetts. The MLSC continued to engage with the life sciences community through the
news media, and digitally through the Weekly Digest, social media platforms, and the MLSC website. The
MLSC also participated in numerous public and private events around the state and nation to explain the
benets of doing business in Massachusetts.
MLSC Marketing and Communications Outreach
The MLSC Weekly
Digest reached
more than 6,000
email subscribers
and had click
rates well above
industry averages
at 9.5%
Posts on the
LinkedIn company
page for the
MLSC averaged
more than 900
impressions in
FY16
The MLSC Twitter
prole more than
doubled the
amount of new
followers from
the previous year
(1,100 vs. 2,700)
The MLSC website
was visited more
than 210,000
times. Spikes
in trafc can be
attributed to new
announcements,
and click-throughs
from the Weekly
Digest
Conferences and Tradeshows
The MLSC participated in trade shows and conferences in Boston, San Francisco, Dubai, and Dusseldorf,
Germany. The Center had its usual strong presence at the 2016 BIO International Convention, and for
the rst time took part in the cluster of events that surround the JP Morgan Healthcare Conference, both
in San Francisco. Through participation in these events the MLSC had the opportunity to connect with
companies from every part of the world and explain the benets of doing business in Massachusetts.
At BIO, we announced the FY17 launch of the Massachusetts Transition and Growth Program (MassTAG -
see next page), the arrival of Biose to Massachusetts, and the expansion of Brammer Bio into Lexington.
MLSC FY16 Annual Report 19
Next Steps
In consultation with stakeholders in government, industry and academia, the MLSC is constantly innovating
and creating new programs that will meet the current and future needs of our life sciences community.
In FY16, the MLSC announced a new convening effort focused on Alzheimer’s Disease, and a funding
program focused on new company recruitment.
Massachusetts Transition and Growth Program
Announced at the BIO International Convention in June 2016, and slated for launch in FY17, the
Massachusetts Transition and Growth Program (MassTAG) will provide grant funding to companies
establishing new operations in the Commonwealth. Critical objectives for this program are job creation
and scientic advancement that will benet patients and further growth of the Massachusetts life sciences
ecosystem.
Awards will be given in grant form to companies with a current workforce of at least ve workers that have an
intention to hire or locate at least ten employees in Massachusetts during the company’s initial twelve months
of operations in the Commonwealth. Grants will be provided on a per-job basis (in amounts comparable to
the awards provided under the MLSC’s existing Job Creation Tax Incentive Program).
Throughout FY16, MLSC President & CEO Travis McCready has made multiple day long visits to communities
outside of the Greater Boston and Cambridge areas. The goal of these visits has been three-fold: to
familiarize the MLSC with the strengths of different regions of the Commonwealth, to gain rst-hand
knowledge of how the MLSC’s previous investments are being utilized to enhance the ecosystem in regions
across the state, and to obtain feedback on ways in which the Center can improve upon our engagement
with communities throughout the Commonwealth. Regional visits included communities such as Pittseld,
Worcester, Lowell, and Franklin.
While each was unique, all visits included a tour at an MLSC funded facility, and roundtable discussions with
industry, academia, and economic development stakeholders in the region. Some key takeaways from the
visits include:
• Lowell’s resurgence and promising future in both biotech and medical devices
• Worcester’s unmatched positioning to be a leader in biomanufacturing
• The unrivaled partnerships that have been formed between industry and academia at UMass Lowell and in
the Franklin Public Schools.
The visits have been a great learning experience for the Center as well as our hosts and as such, more visits
are currently in the works for FY17.
Learning Through Regional Visits
MLSC FY16 Annual Report20
Massachusetts Center for Alzheimer Therapeutics Science
The Massachusetts Life Sciences Center’s Neuroscience Consortium, founded in 2012, is a pioneering model
designed to leverage Massachusetts’ rich environment of neurobiology and neuroscience. The goal of this
consortium was to bring together industry and academic partners dedicated to solving some of the most
intractable neurodegenerative diseases. In previous years, industry members have contributed a total of
$3.25 million to support the research of 12 investigators studying Alzheimer’s, Multiple Sclerosis, Parkinson’s,
Neuropathic Pain and Amyotrophic Lateral Sclerosis (ALS).
In its latest round, the consortium decided to focus their efforts on Alzheimer’s Disease, culminating in
the launch of the Massachusetts Center for Alzheimer Therapeutics Science (MassCATS). Alzheimer's
is one of the leading causes of death in the United States for which there is no known cure. Alzheimer’s
currently affects more that 5 million Americans, with the number of new diagnoses expected to skyrocket
in the next decade. MassCATS brings scientists in Massachusetts and across the country together with
biopharmaceutical industry partners in a new effort to nd effective treatments and cures for Alzheimer’s
disease. Industry partners - AbbVie, Biogen, Janssen Pharmaceuticals Inc., Merck and Sunovion
Pharmaceuticals - have collectively committed $1.25 million in Alzheimer’s-related research funding.
Through MassCATS, neuroscientists from Massachusetts General Hospital (MGH), Harvard Medical School,
Broad Institute, Whitehead Institute, MIT, Picower Institute for Learning and Memory, Emory University
School of Medicine in Atlanta, and the Rush University Medical Center in Chicago will collectively use
industry and academic resources and the expertise of their respective labs to validate and move targets
toward an effective therapy for Alzheimer’s.
Academic leads are developing platforms that will be shared across the consortium. In addition,
bioinformatics experts on the teams are developing the MassCATS DataLens, a unique repository for
sharing and analyzing large public domain data sets, as well as research data, to facilitate and accelerate
data sharing.
The new Center will operate out of MGH under the leadership of Dr. Bradley Hyman, and project teams will
be comprised of academic and industry scientists working together to share knowledge and resources. To
facilitate this effort, industry partners are providing special purpose libraries of compounds to enable further
exploration of the biology and therapeutic potential of new target ideas.
“In working with the Massachusetts Life Sciences Center and collaborators in the
biopharmaceutical industry, investigators will have access to shared expertise
and resources to accelerate the testing of new ideas while designing innovative
ways to translate them toward new treatments for our patients”
- Dr. Bradley T. Hyman, Director, Massachusetts Alzheimer’s Disease Research Center at MGH
MLSC FY16 Annual Report 21
Change is never easy. While the status quo provides familiarity and comfortability, progress requires
innovation and experimentation. We needn’t look too far back in our own state’s history to see what
complacency can mean for our leadership of an industry, whether it be textiles, or computers. As the life
sciences industry evolves, our approach to supporting the industry’s future growth will need to evolve as
well.
We’ve seen signicant change here at the MLSC over the past year. We want to thank Scientic Advisory
Board Chairman Harvey Lodish for his many contributions to the work of the MLSC, along with our outgoing
Board members, Dana-Farber President & CEO Ed Benz, Ininity Pharmaceuticals Chair, President & CEO
Adelene Perkins, and recently retired Vice President for Economic Development for the University of
Massachusetts Tom Chmura, who often represented the UMass President on our Board. We owe each of
them a debt of gratitude for being so generous with their time, knowledge and leadership and wish them all
the best in future endeavors.
The state budget provides for an FY17 investment fund appropriation of $10 million, contingent on the
State Comptroller’s declaration of a consolidated net surplus for FY 2016. The MLSC appreciates, and is
grateful to Governor Baker and his Administration, and the State Legislature under the leadership of Senate
President Stan Rosenberg and Speaker of the House Robert DeLeo, for prioritizing this funding within the
state budget. We look forward to working with these leaders and our partners in industry and academia as
we chart the path forward for “Life Sciences 2.0”.
The Way Forward
Appendices
Awardee Total Award Year of Award Funding Status at End of
FY 2016
Bay Path College $50,000 FY 2013 Completed
Bay Path University $500,000 FY 2015 Ongoing
BayState Medical Center/Health Informatics & Technology Innovation Center $5,500,000 FY 2013 Ongoing
Berkshire Community College $500,000 FY 2015 Ongoing
Boston Children's Hospital $4,014,031 FY 2013 Completed
Boston Children's Hospital $2,263,133 FY 2015 Ongoing
Boston University Biomedical Lab and Clinical Sciences Program $180,000 FY 2015 Completed
Boston University Business Innovation Center $363,750 FY 2015 Ongoing
Boston University Medical School $1,743,648 FY 2015 Ongoing
Brigham & Women's Hospital $2,603,537 FY 2015 Ongoing
Bunker Hill Community College $200,000 FY 2013 Completed
Cape Cod Community College $395,485 FY 2014 Completed
City of Taunton $55,000 FY 2014 Completed
Dana Farber Molecular Cancer Imaging Center $10,000,000 FY 2012 Completed
Framingham State University $3,000,000 FY 2014 Completed
Framingham Wastewater and Pumping Station $12,860,534 FY 2009 Completed
Harvard Medical School $5,000,000 FY 2013 Ongoing
Holyoke Community College $3,800,000 FY 2013 Completed
Holyoke Community College $300,000 FY 2015 Ongoing
Joslin Translational Center for the Cure of Diabetes $5,000,000 FY 2012 Completed
Just-A-Start $46,099 FY 2014 Completed
Just-A-Start $49,992 FY 2015 Completed
LabCentral $4,955,515 FY 2013 Completed
LabCentral $5,000,000 FY 2014 Ongoing
MA Green High Performance Computing Center $4,540,000 FY 2013 Ongoing
Marine Biological Laboratory in Woods Hole $10,000,000 FY 2009 Completed
Massachusetts Institute of Technology $1,838,000 FY 2015 Ongoing
MassBay Community College $50,000 FY 2014 Completed
MassBiologics-UMass Medical School $5,000,000 FY 2014 Ongoing
Middlesex Community College $36,664 FY 2013 Completed
Middlesex Community College $3,000,000 FY 2014 Ongoing
Mount Wachusett Community College $500,000 FY 2014 Ongoing
Museum of Science "Hall of Human Life" $5,000,000 FY 2012 Completed
New Bedford Economic Development Council $75,000 FY 2014 Completed
North Shore Biotech Consortium $5,000,000 FY 2014 Ongoing
Northern Essex Community College $1,242,000 FY 2013 Completed
Pittseld Economic Development Authority $55,000 FY 2013 Completed
Pittseld Economic Development Authority $9,670,000 FY 2014 Ongoing
Quincy College $78,799 FY 2013 Completed
Quincy College $500,000 FY 2014 Ongoing
Quinsigamond Community College $310,000 FY 2013 Completed
Quinsigamond Community College $499,880 FY 2014 Completed
Quinsigamond Community College $5,000,000 FY 2015 Ongoing
Regis College $50,000 FY 2013 Completed
Regis College $355,000 FY 2015 Ongoing
Capital Investment Awards From Inception Through
June 30, 2016
Awardee Total Award Year of Award Funding Status at End of
FY 2016
Roxbury Community College $3,000,000 FY 2015 Ongoing
Springeld Technical Community College $85,673 FY 2013 Completed
Springeld Technical Community College $972,850 FY 2015 Ongoing
The Forsyth Institute $4,133,215 FY 2013 Completed
The Forsyth Institute $2,210,229 FY 2015 Ongoing
Tufts/Cummings School of Veterinary Medicine, NE Regional Biosafety Lab in Grafton $9,500,000 FY 2009 Completed
UMass Amherst Life Sciences Laboratories $95,000,000 FY 2013 Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy $2,000,000 FY 2011 Ongoing
UMass Boston /Dana Farber Center for Personalized Cancer Therapy Expansion $8,000,000 FY 2014 Ongoing
UMass Boston VDC $588,848 FY 2014 Ongoing
UMass Dartmouth Advanced Technology Manufacturing Center (ATMC) $11,400,000 FY 2012 Completed
UMass Lowell Emerging Technologies and Innovation Center $10,000,000 FY 2012 Completed
UMass Lowell Innovation Hub $1,000,000 FY 2014 Ongoing
UMass Lowell M2D2 $4,046,697 FY 2014 Ongoing
UMass Medical School $5,000,000 FY 2015 Ongoing
UMass Medical School Albert Sherman Center $90,000,000 FY 2010 Completed
UMass Medical School/Vector Manufacturing Center $20,600,000 FY 2012 Completed
Venture Cafe $347,000 FY 2014 Ongoing
Wellesley College $50,000 FY 2015 Ongoing
Western New England University $500,000 FY 2014 Completed
Worcester Polytechnic Institute (Biomanufacturing Education & Training Center) $5,150,000 FY 2010 Completed
Capital Investment Awards From Inception Through
June 30, 2016
Total Number of Projects 66
Total Investment in Capital Projects $394,765,579
Total Number of Projects for Which MLSC Funding is Complete 34
Total Investment in Projects for Which MLSC Funding is Complete $213,372,887
Total Number of Ongoing Projects 32
Total Investment in Ongoing Projects $181,392,692
Total Number of Projects for Which MLSC Funding was Completed in FY16 11
Total Investment in Projects for Which MLSC Funding was Completed in FY16 $22,961,859
A Chemtek, Inc. Worcester
AB Biosciences, Inc. Boston
Abpro Labs Woburn
Access Vascular, Inc. Woburn
Acetylon Pharmaceuticals, Inc. Boston
AdMeTech Foundation Boston
Advanced Instruments, Inc. Norwood
Advanced Radiation Therapy, LLC Tyngsboro
Advanced Research and Development (ARD) Lexington
AdvanDx, Inc. Woburn
Agilux Laboratories Worcester
Akaza Research , LLC (DBA Open Clinica) Waltham
Akrivis Technologies, LLC Cambridge
Alacrita LLC Cambridge
Albright Technologies, Inc. Leominster
Allurion Technologies Wellesley
Alzheimer Disease Center Quincy
Amplyus Cambridge
Anderson Biotest, LLC Boston
Antera Therapeutics Cambridge
Aphios Corporation Woburn
Artaic, LLC Boston
Arteriocyte Medical Systems Hopkinton
Asaman, Inc. Avon
Atlantic Lab Equipment, LLC Salem
Avaxia Biologics, Inc. Lexington
Averica Discovery Services, Inc. Marlborough
AVIA Biosystems LLC Norton
Bach Pharma, Inc North Andover
Barrett Technology, Inc. Newton
Berkshire Sterile Manufacturing, Inc. Lee
BethCare, Inc. Boston
Bio2 Technologies Woburn
Biomedical Research Models, Inc. Worcester
BioScale, Inc. Lexington
BioSensics LLC Cambridge
BioVolutions, Inc. Woburn
Blend Therapeutics, Inc. Watertown
Blue Sky Biotech, Inc. Worcester
Blue Stream Laboratories Woburn
Boston 3T Biotechnologies Fall River
Boston MedTech Advisors Dedham
Boston Microuidics, Inc. Medford
Boston Micromachines Corporation Cambridge
Boyd Technologies Lee
Cam Med, LLC West Newton
Catapult Product Development, Inc. Waltham
Celldex Therapeutics, Inc. Fall River
CellMosaic, LLC Worcester
Celltreat Scientic Products Shirley
CeQur Corporation Marlborough
Cerulean Pharma, Inc. Cambridge
2015-2016 Internship Challenge Host Companies
Cisbio US, Inc. Bedford
CMC Consulting Boston, Inc. Framingham
Cocoon Biotech, Inc. Lowell
Collegium Pharmaceutical, Inc. Canton
Constant Therapy, Inc. Lexington
CONTINUUS Pharmaceuticals, Inc. Woburn
Corbus Pharmaceuticals, Inc. Norwood
Courtagen Life Sciences, Inc. Woburn
Covaris, Inc. Woburn
CreaGen Biosciences Inc. Woburn
CryoXtract Instruments, LLC Woburn
CSA Medical, Inc. Lexington
CuriRx, Inc. Wilmington
CYTO Consulting Lexington
Cytrellis Biosystems, LLC Boston
Daktari Diagnostics, Inc. Cambridge
Delsys, Inc. Natick
Dermal Photonics Corporation Middleton
Detector Technology, Inc. Palmer
DNA Medicine Institute Cambridge
DocBox, Inc. Newton
Dyax Corp Burlington
Embera Neuro Therapeutics, Inc. Sudbury
EnBiotix, Inc. Boston
enEvolv, Inc. Cambridge
Enumeral Biomedical Cambridge
Environmental Health, Inc. Dover
EpigenDx, Inc. Hopkinton
Essential Life Solutions Ltd Stoughton
Etiometry, LLC Boston
Everost, Inc. Sturbridge
Extend Biosciences, Inc. Cambridge
EyeNetra, LLC Somerville
Fairbanks Pharmaceuticals Concord
First Light Biosciences, Inc. Bedford
Five Star Manufacturing, Inc. New Bedford
FloDesign Sonics Wilbraham
Flow Forward Medical, Inc. Lowell
Fractyl Laboratories Inc. Lexington
G & F Medical, Inc. Danvers
Gecko Health Innovations, Inc. Cambridge
Gel4Med Brighton
Genocea Biosciences, Inc. Cambridge
GenoSpace, LLC Cambridge
Giner, Inc. Newton
Guided Surgery Solutions, LLC Wellesley Hills
Gweepi Medical, Inc. Cambridge
Harvard Apparatus Regenerative Technology Holliston
Health Policy Associates, Inc. (FKA HPA Ventures) Westwood
HelixBind, Inc. Marlborough
Hemedex Inc. Cambridge
Imagine Optic Inc. Boston
InCrowd, Inc. Boston
Infraredx, Inc. Burlington
Institute for Pediatric Innovation, Inc. Cambridge
inviCRO, LLC Boston
InVivo Therapeutics Corporation Cambridge
iOmics Corporation Cambridge
IonSense Saugus
iSpecimen, Inc. Lexington
iWalk (DBA "BiOM") Bedford
Jounce Therapeutics Cambridge
KBioBox, Inc. Worcester
KeraFAST Boston
KnipBio Harvard
Labminds, Inc. Boston
Lariat Biosciences, Inc. Beverly
Lattice Automation, Inc. Boston
Launchpad Medical Boston
LaVoie Strategic Communications Cambridge
LayerBio, Inc. Arlington
Life Science Nation Boston
Lighthouse Proteomics, LLC Beverly
Little Sparrows Technologies, LLC Winchester
Macrogen Corp Boston
Matrivax R&D Corporation Boston
Mayly Company Brighton
MCR Labs, LLC Framingham
MedPanel Cambridge
Medrobotics Raynham
MedTechna, Inc. Dedham
Merrimac Ventures, LLC (DBA Avastus Preclinical
Services
Cambridge
Metastat, Inc. Boston
Microbiome Health Research Institute (OpenBiome) Medford
Microbiotix, Inc. Worcester
Micro-Leads, Inc. Boston
MiMecore Therapeutics Beverly
Mouse Specics, Inc. Quincy
MX Orthopedics Billerica
Myomo, Inc. Cambridge
N2 Biomedical, LLC. Bedford
Nano Terra Inc. Cambridge
NEHI, Inc. Cambridge
Nemucore Medical Innovations, Inc. Worcester
NeuroFieldz, Inc. Newton
NeuroScouting LLC Cambridge
New England Peptide, LLC Gardner
Nexcelom Bioscience LLC Lawrence
NexGen Arrays, LLC Boston
NinePoint Medical, Inc. Cambridge
Nix, Inc. Cambridge
Northpaw Ventures Corp (DBA OnDeckBiotech) Cambridge
Nonspec Inc. Carlisle
2015-2016 Internship Challenge Host Companies
Nuclea Biotechnologies, Inc. Pittseld
Olaris Therapeutics, Inc Cambridge
OMNI Life Science, Inc. East Taunton
PatientsLikeMe, Inc. Cambridge
Pear Therapeutics Boston
Persomics USA Waltham
Phosphorex, Inc. Hopkinton
PLC Medical Systems, Inc. Brighton
PNA Innovations, Inc. Woburn
Podimetrics, Inc. Cambridge
Polestar Technologies Needham
Polycarbon Industries (PCI Synthesis, Inc) Newburyport
Portal Instruments, Inc. Cambridge
Precision Fabricators Ltd. Stoughton
Pressure BioSciences, Inc. South Easton
Privo Technologies Cambridge
Putnam Associates Burlington
Quad Technologies LLC Beverly
Quantum Diamond Technologies, Inc. Somerville
Ra Pharmaceuticals Cambridge
RainDance Technologies, Inc. Billerica
RAN Biotechnologies, Inc. Beverly
Ras Labs, LLC Quincy
Real Food Solutions, LLC Cambridge
Respiratory Motion, Inc. Waltham
ReWalk Robotics, Inc. Marlborough
Riparian Pharmaceuticals, Inc. Cambridge
Robie Device Group, LLC North Andover
Rogers Sciences, Inc. Boston
Rubius Therapeutics, Inc. Cambridge
RXi Pharmaceuticals Marlboro
S2N Health, LLC Newton
SafePath Medical, Inc. Methuen
Safety Partners, Inc. Bedford
Sage Product Development, Inc. North Attleboro
SBH Sciences, Inc. Natick
Securus Medical Group, Inc. Beverly
Seeding Labs Boston
Selecta Biosciences, Inc. Boston
SemiNex Corporation Peabody
Senscio Systems, Inc. Boxboro
seqWell, Inc. Beverly
SevenOaks Biosystems Boston
Shaser, Inc. Woburn
Sproxil, Inc. Cambridge
SRS Medical Systems, Inc. North Billerica
STAR Analytical Services (Speech Technology and
Applied Research)
Bedford
STC Biologics, Inc. Cambridge
Sync Think, Inc. Boston
T2 Biosystems, Inc. Lexington
TARIS Biomedical, LLC Lexington
2015-2016 Internship Challenge Host Companies
Thermedical, Inc. Waltham
Thync, Inc. Boston
TRA360 (Tim Rosa Associates) Waltham
Triple Ring Technologies, Inc. Lynneld
Triple Sharp Venture Engineering, LLC Topseld
Ubiqi Health, Inc. (DBA Klio Health) Somerville
Union Biometrica, Inc. Holliston
VasoTech, Inc. Lowell
Vaxess Technologies, Inc. Cambridge
Vedanta Biosciences, Inc. Boston
Veritas Genetics, Inc. Beverly
Viatar LLC Lowell
Virtudent Boston
Visterra, Inc. Cambridge
VitaThreads, Inc. Worcester
Vittamed Corporation Lexington
Vivonics, Inc. Waltham
VocaliD, Inc. Belmont
WorldCare Clinical, LLC Boston
X-CHEM, Inc. Waltham
Xtal BioStructures, Inc. Natick
ZS Genetics, Inc. Wakeeld
Guided Surgery Solutions, LLC Wellesley
Hepatochem, Inc. Cambridge
Immunexcite, Inc. Lexington
InsomniSolv, Inc. Beverly
Instrumentation Laboratory Company Bedford
inviCRO, LLC Boston
Jounce Therapeutics, Inc. Cambridge
Juno Therapeutics, Inc. Waltham
KEW Group Inc. Cambridge
Lantern Pharma, Inc. Cambridge
LayerBio, Inc. Arlington
LeMaitre, Inc. Burlington
LFB USA, Inc. Framingham
Lightlab Imaging, Inc. Westford
Lumicell Diagnostics, Inc. Wellesley
LX Medical Corporation Westwood
Masy Systems, Inc. Pepperell
Matrivax R&D Corporation Boston
MCC Global Laboratories, Inc. Beverly
MedicaMetrix, Inc. Wayland
Merrimack Pharmaceuticals, Inc. Cambridge
Micro-Leads, Inc. Boston
Moderna Therapeutics, Inc. Cambridge
Momenta Pharmaceuticals, Inc. Cambridge
MX Orthopedics, Corp. Lexington
Myomo, Inc. Cambridge
New England Biolabs, Inc. Ipswich
NinePoint Medical, Inc. Cambridge
Nitto Denko Avecia Inc. Milford
Nova Biomedical Corporation Waltham
NxStage Medical, Inc. Lawrence
OMNIlife science, Inc. Taunton
Pall Corporation Westborough
PAREXEL International Corporation Lowell
Parsagen Diagnostics, Inc. Boston
PathMaker Neurosystems, Inc. Boston
PerkinElmer, Inc. Waltham
Pharmalucence, Inc. Bedford
Philips Electronics North America Andover
Platelet Biogenesis, Inc. Chestnut Hill
PNP Research Corporation Drury
Quanterix Corporation Cambridge
Quest Diagnostics, Incorporated Cambridge
Ra Pharmaceuticals, Inc Cambridge
Radius Health, Inc. Waltham
Revolution Biosciences LLC Boston
Riparian Pharmaceuticals Boston
Sano, Inc. Cambridge
Sarepta Therapeutics, Inc. Cambridge
3Derm Systems, Inc. Cambridge
908 Devices, Inc. Boston
AbbVie Inc Worcester
Abiomed, Inc. Danvers
Aegerion Pharmaceuticals, Inc. Cambridge
Agile Devices Inc. Cambridge
Akili Interactive Labs Inc. Boston
Akita Innovations, Inc. North Billerica
Akrivis Technologies LLC Cambridge
Alcyone Lifesciences, Inc. Concord
Alexion Pharmaceuticals, Inc. Lexington
Alkermes, Inc. Waltham
Allurion Techologies, Inc. Wellesley
Alnylam Pharmaceuticals, Inc. Cambridge
Amgen Inc. Cambridge
Aquinnah Pharmaceuticals, Inc. Cambridge
Arch Therapeutics, Inc. Framingham
Barrett Technology Inc. Newton
Bind Therapeutics, Inc. Cambridge
Bio2 Technologies, Inc. Woburn
Biogen, Inc. Cambridge
Bluebird Bio, Inc. Cambridge
Blueprint Medicines Corporation Cambridge
Boston Heart Diagnostics Corporation Framingham
Bruker Corporation Billerica
Cam Med LLC West Newton
Cell Signaling Technology Danvers
Charles River Laboratories, Inc. Wilmington
Charm Sciences, Inc. Lawrence
Cognition Medical Corp. Cambridge
Covaris, Inc. Woburn
Cre8MDI LLC Cambridge
Cristcot Medical, Inc. Sudbury
CSA Medical, Inc. Lexington
DePuy Othopaedics, Inc. Raynham
DetectonGen Inc. Grafton
EMD Millipore Corporation Billerica
Emulate, Inc. Boston
Enanta Pharmacueticals, Inc. Watertown
Energesis Pharmaceuticals Inc. Cambridge
Epizyme, Inc. Cambridge
Eutropics Pharmaceuticals, Inc. Cambridge
Excellims Corporation Acton
Extend Biosciences Inc. Cambridge
Felicitex Therapeutics Inc. Newton
First Light Biosciences, Inc. Bedford
Foundation Medicine, Inc. Cambridge
GE Healthcare Bio-Sciences Corp. Marlborough
Ginko Bioworks, Inc. Boston
List of Certified Active Life Sciences Companies as of June 30, 2016
As part of the MLSC's award process, any for-prot company that receives funds through any of the MLSC's
competitive programs must be certied as a "certied life sciences company" in accordance with the MLSC's
statutory authority. The companies below are currently certied by the MLSC.
List of Certified Active Life Sciences Companies as of June 30, 2016
SBH Sciences, Inc. Natick
Seres Therapeutics, Inc. Cambridge
Shire Human Genetic Therapies, Inc. Lexington
SMC Ltd Sterling
SQZ Biotechnologies Company Boston
STC Biologics, Inc. Cambridge
Strohl Medical Technologies, Inc. Weymouth
Takeda Pharmaceuticals America, Inc. Cambridge
T2Biosystems, Inc. Lexington
Triton Systems, Inc. Chelmsford
uniQure, Inc. Lexington
Vaxess Technologies, Inc. Cambridge
Web Industries Boston, Inc. Holliston
Windgap Medical Somerville
Wolfe Laboratories, Inc. Watertown
As part of the MLSC's award process, any for-prot company that receives funds through any of the MLSC's
competitive programs must be certied as a "certied life sciences company" in accordance with the MLSC's
statutory authority. The companies below are currently certied by the MLSC.
Massachusetts Life Sciences Center Board of
Directors as of June 30, 2016
Jay Ash, Co-Chair
Secretary, Executive Ofce of Housing and Economic Development
Kristen Lepore, Co-Chair
Secretary, Executive Ofce for Administration and Finance
Edward J. Benz, Jr., M.D.
President and CEO, Dana-Farber Cancer Institute
Martin Meehan
President, University of Massachusetts
Adelene Perkins
Chair, President and Chief Executive Ofcer, Innity Pharmaceuticals
Lydia Villa-Komaroff, Ph.D.
Director and Retired Founding CEO, Cytonome/ST
Peter Parker, Ph.D.
President, BioInnovation LLC, Co-Founder, LabCentral
Massachusetts Life Sciences Center Scientific
Advisory Board as of June 30, 2016
Hillel Bachrach Dale Larson
Chairman - Viztek & UltraSPECT Director of Biomedical Systems - Draper Laboratory
James Barry Ph.D. Judith Lieberman Ph.D. M.D.
Executive Vice President & Chief Operating Ofcer - InspireMD Inc.
Senior Investigator Immune Disease Institute - Children’s Hospital Boston and
Professor of Pediatrics - Harvard Medical School
Kevin J. Bitterman Ph.D. Lita L. Nelsen
Principal - Polaris Venture Partners
Former Director Technology Licensing Ofce - Massachusetts Institute of
Technology
Dalia Cohen Ph.D. Barbara Osborne Ph.D.
Head of Research - Beryllium
Professor of Veterinary and Animal Sciences - University of Massachusetts
Amherst
James J. Collins Ph.D. Carmichael Roberts Ph.D.
Professor of Biomedical Engineering & Science - Massachusetts Institute of
Technology
Partner - North Bridge Venture Partners
John M. Collins Ph.D. Frederick J. Schoen M.D. Ph.D.
Chief Operating Ofcer - Center for Integration of Medicine & Innovative
Technology (CIMIT)
Executive Vice-Chairman Department of Pathology at Brigham and Women’s
Hospital
T. (Teo) Forcht Dagi M.D. Lauren Silverman Ph.D.
Chairman - CV6 and healthEgames Managing Director - Novartis Option Fund
Robert D’Amato M.D. Ph.D. Alison Taunton-Rigby Ph.D.
Judah Folkman Chair in Surgery and Director - Center for Macular
Degeneration Research Children’s Hospital Boston
Co-Founder, Chief Executive Ofcer and Director - RiboNovix Inc.
Glenn R. Gaudette Ph.D. Guillermo Tearney M.D. Ph.D.
Associate Professor Biomedical Engineering - Worcester Polytechnic Institute Professor of Pathology - Harvard Medical School
José-Carlos Gutiérrez-Ramos Ph.D. David Walt Ph.D.
President and Chief Executive Ofcer - Synlogic Inc
Robinson Professor of Chemistry and Howard Hughes Medical Institute
Professor - Tufts University
Henry Kay
U.S. Partner - Medica Venture Partners
Front Row L-R
Rob Ramos
Tal Dinnar
Emily Azcue
Cheryl Sadeli
Nancy Goryl
Sandhya Iyer
Monica Anc
Brad Rosenblum
Pamela Norton
Back Row L-R
Ryan Mudawar
Colin Donnelly
Ben Bradford
Dami Aina
Travis McCready
Angus McQuilken
Karyn Hoffman
Beth Nicklas
Cheryl Purnell
Barb Platt
MLSC Sta
MASSACHUSETTS LIFE SCIENCES CENTER
1000 WINTER STREET SUITE 2900
WALTHAM MASSACHUSETTS 02451
WWW.MASSLIFESCIENCES.COM
INFO@MASSLIFESCIENCES.COM
